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Abstract. In a randomized controlled trial, chloroquine monotherapy was compared with the combination of arte-
sunate and chloroquine for treating uncomplicated Plasmodium falciparum malaria in 536 Gambian children. Chloro-
quine-treated children exhibited a 28-day clinical failure rate of 15% (95% confidence interval [CI]  9.2−22%)
compared with 11% (7.8−15%) among children receiving the combination (P 0.08, by Wilcoxon test). Seventy-three
percent of chloroquine-treated children exhibited parasitemia during follow-up compared with 49% of children receiving
the combination (relative risk  1.5, 95% CI  1.3−1.7; 2  21.18, P < 0.001). A significant reduction in clinical and
parasitologic treatment failure in the combination group occurred in the first two weeks following treatment, but this was
eroded over weeks three and four of follow-up. The impact of combination therapy on the transmission of chloroquine-
resistant parasites is discussed. Chloroquine plus artesunate is not sufficiently efficacious to justify its introduction as a
replacement for chloroquine monotherapy in The Gambia.
INTRODUCTION
Chloroquine (CQ) remains the front-line treatment for un-
complicated Plasmodium falciparum malaria in much of Af-
rica. In The Gambia in west Africa, evidence is accumulating
that the prevalence of resistance to CQ is increasing.1–4 A
change in treatment policy may be required soon because an
increase in the prevalence of CQ-resistant P. falciparum in-
fections has been linked to increasing malaria-related mortal-
ity among children in neighboring Senegal.5 The combination
of sulfadoxine with pyrimethamine (SP) has been suggested
as an affordable replacement drug for CQ. However, wide-
spread use of SP has very rapidly resulted in the development
of resistance among parasite populations in east Africa and in
Malawi6,7 Thus, use of SP alone in The Gambia may provide
only a short-term benefit.
In the context of increasing prevalence of CQ resistance in
The Gambia, we have shown that treatment with CQ in 1998
preferentially selected for emergent gametocytes carrying re-
sistance-associated alleles of the P. falciparum multidrug re-
sistance gene 1 (pfmdr1) and the P. falciparum chloroquine
resistance transporter (pfcrt) gene.4 The long-term public
health benefit of using combination therapy in African set-
tings will be realized only if such selective transmission is
prevented. Therefore, drug combinations need to be evalu-
ated both in terms of their efficacy/effectiveness and the
transmission dynamics of parasites resistant to any of the
component drugs.
One plausible strategy for sustainable therapeutic success
for uncomplicated malaria cases is to introduce CQ plus arte-
sunate (AS) as a combination therapy. This would leave SP,
and other anti-folate combinations such as chlorproguanil/
dapsone, in reserve if required for the treatment of recrudes-
cent infections. The combination of SP with AS has been
shown to be highly efficacious in The Gambia8 and has the
added benefit of significantly reducing post-treatment trans-
mission compared with treatment with either CQ or SP
alone.9 In this report, we evaluate the efficacy of CQ plus
three daily doses of AS compared with CQ monotherapy as
treatment for uncomplicated P. falciparum malaria in Gam-
bian children.
MATERIALS AND METHODS
The study protocol was reviewed and approved by the
Medical Research Council/Gambian Government Joint Ethi-
cal Committee, and the London School of Hygiene and
Tropical Medicine Ethics Committee. Informed consent was
obtained from the parents or guardians of all patients who
participated in this study.
Study children and treatment.An established protocol for
clinical trials with gametocyte carriage and transmission as
the major endpoints9 was modified to measure additional end
points of clinical failure, post-treatment parasite prevalence,
and post-treatment parasite density. Children attending the
clinic at Farafenni General Government Hospital in Farafenni,
The Gambia were recruited from October 4 to December 5,
2000. Farafenni is a market town in a rural area 170 km from
the Atlantic coast. Eligible children were 1−9 years old, lived
within a radius of approximately 10 km of Farafenni (but not
in nearby Senegal), had a body weight >5 kg, a history of
fever, and P. falciparum asexual parasitemia >500/L of cap-
illary blood. Eligible children were only recruited if a parent
or guardian gave informed consent. Exclusion criteria in-
cluded anemia (packed cell volume [PCV] <20%), any signs
or symptoms of severe malaria, inability to take drugs orally,
treatment with any anti-malarial within the past two weeks,
infection with either P. ovale or P. malariae, or any evidence
of chronic disease or other acute infection.
Recruits were randomly assigned to receive three doses of
CQ alone or CQ plus three doses of AS in a ratio of 1:3, using
random numbers generated in Stata 6.0 (Stata Corp., College
Station, TX). The study was designed primarily for transmis-
sion end points, and this ratio was chosen to give approxi-
mately equal gametocyte carriage rates at day 7.9 A sample
size of 500 was expected to provide sufficient statistical power
to observe a difference in transmissibility of gametocytes aris-
ing after the two regimens. Study clinicians and field assistants
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(who administered treatment) were not blinded to the treat-
ment given to each recruited child. However, the principal
investigator, entomologist, and slide readers were unaware of
the treatment group of each child until the conclusion of the
study.
Children in the CQ treatment group were orally adminis-
tered 25 mg of CQ base (Alkaloida, Ltd., Tiszavasvari, Hun-
gary) per kilogram of body weight over a three-day period.
Children in the CQ plus AS group received 25 mg/kg of CQ
base and 4 mg/kg of AS (Guilin Pharmaceutical Works, Gui-
lin, People’s Republic of China and supplied by Sanofi, Paris,
France) daily for three days. No artesunate placebo was given
to the children on CQ monotherapy. All drugs were pre-
scribed by a study clinician who directly supervised the first
dose. The second and third doses were supervised by a
trained field assistant in the child’s home. Children were ob-
served for 30 minutes after the first dose, and any child who
vomited was administered a replacement dose. Study num-
bers were not assigned until this first dose was successfully
administered. Children who repeatedly vomited oral treat-
ment were given CQ as an injection, or admitted to the pe-
diatric ward of the hospital. These children were not assigned
a study number, and the next eligible child was recruited in
their place, with the same treatment. Each child also received
10 mg/kg of paracetamol under supervision in the recruitment
clinic, and parents or guardians were given further doses of
paracetamol and instructed to administer it every six hours
until the child’s symptoms had subsided. Parents or caretak-
ers were asked to return to the clinic on any day if the child’s
condition deteriorated or showed reason for concern.
If at any time during the four-week follow-up period a
parent or guardian reported that a child was unwell, the child
was examined by a physician. If the child had a parasitemia
and fever (axillary temperature 37.5°C) and did not have
other conditions that could explain the symptoms, the child
was considered a clinical treatment failure and given SP (half
a tablet for children weighing 10 kg and an additional quar-
ter tablet for each 5-kg increase in body weight; each tablet
contained 12.5 mg of pyrimethamine and 250 mg of sulfadox-
ine) as a rescue treatment.
Laboratory samples. Peripheral blood from a finger prick
in the recruiting clinic provided samples for duplicate thick
blood films, a hematocrit capillary tube, and an EDTA-
microtainer sample (50−100 L) from each patient prior to
treatment (day 0). One thick film was stained rapidly using
Field’s method and 20 high-power microscopic fields were
read immediately in the clinic for diagnosis. Second blood
films were returned to the laboratory and allowed to dry for
24 hours. Thick films collected at all time points were stained
with Giemsa and were read twice, each time by a different
trained microscopist; 100 high-power fields were examined by
each reader before a slide was declared negative. For all thick
films in the study, parasite density per microliter of blood was
calculated assuming one parasite per high-power field is
equivalent to 500 parasites per L.10
Post-treatment follow-up. In addition to visiting on days 1
and 2 to administer antimalarial treatment, field assistants
visited each child at home on post-recruitment days 3, 14, and
28. On each occasion, a finger prick blood sample was taken
and used to make a thick film for microscopy. The child or
child’s parents were asked whether there had been improve-
ment in the patient’s condition, and whether there had been
any relapse of symptoms. If on any of these visits the field
assistant thought there was evidence of continuing or relaps-
ing clinical malaria, the child was asked to attend the clinic as
soon as possible for appraisal by a clinician and further treat-
ment if necessary.
On day 7 after treatment, all patients were collected from
their homes and taken to the Medical Research Council
Laboratories in Farafenni, where peripheral blood was ob-
tained by finger prick for thick blood film preparation and
PCV estimation. Thick blood films were stained with Field’s
stain, and 100 fields were immediately examined for the pres-
ence of trophozoites or gametocytes. Gametocyte-positive
subjects were asked to donate venous blood for transmission
studies.9
Data analysis.All children with follow-up data were in-
cluded in the primary analysis. Clinical failure rates were es-
timated using the Kaplan-Meier method.11 Treatment failure
rates were compared using the Wilcoxon test. All data were
double-entered into Epi-Info version 6.0 (Centers for Disease
Control and Prevention, Atlanta, GA). In the case of micros-
copy data, both first and second readings were double-
entered and the files were merged before the two readings
were compared. Discrepancies in parasite density > ±40%
were resolved by re-reading of the relevant thick films. Clini-
cal and parasitologic data entered in Epi-Info were trans-
ferred to Stata 6.0 (Stata Corp.) for statistical analysis.
RESULTS
A profile of the study is shown in Figure 1. A total of 1,502
children with fever (axillary temperature 37.5°C) were
screened. Nine hundred sixty-six were not eligible for enroll-
ment. The most common reasons for ineligibility were slide
negativity (n  434), use of CQ in the previous two weeks
(n  110), refusal to give consent (n  100), P. falciparum
parasite density <500/L (n  59), living outside the study
area (n 57), repeated vomiting of medicine (n 51) and a
PVC <20% (n  29). Five hundred thirty-six children were
recruited, 136 and 400 in the two treatment groups, respec-
tively (ratio  1:2.9). The baseline characteristics of the two
groups are shown in Table 1.
Of the 536 recruits, 21 children (7 and 14 in the CQ and
CQ/AS groups, respectively) were found by additional mi-
croscopy to have no detectable P. falciparum and were there-
fore incorrectly read by the microscopists during the rapid
screening procedure in the recruiting clinic. Seven of them
were positive for P. malariae or P. ovale. An additional 18
recruited children (3 and 15 in the monotherapy and combi-
nation groups, respectively) were found to be positive at re-
cruitment for either P. malariae or P. ovale, in addition to P.
falciparum. These 39 children have been included in the pri-
mary analyses and in the trial profile, but were excluded in a
secondary analysis.
Three fully observed doses of antimalarials were docu-
mented for 95.0% of the recruited children. Twenty-one chil-
dren withdrew from the study during the first 48 hours for one
of the following reasons: the child left the area (n  5), the
guardian gave a false address (n 5), consent was withdrawn
(particularly by the child’s father) (n  5), the parents took
the child for additional treatment elsewhere (these may have
been treatment failures) (n 2), the child died (n 1), and
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other reasons (n  3). None of these children was available
for any subsequent follow-up visits. For six additional chil-
dren, treatment data were not recorded on days 1 and 2; two
of these children were among the 21 with no detectable P.
falciparum parasitemia at recruitment. Thus, 472 recruited
children (120 and 352 in the respective treatment groups)
presented with a confirmed P. falciparum monoinfection and
completed the treatment course under observation.
Six percent of children in each group were not seen on one
of the scheduled follow-up days, but were seen on a later
follow-up day. For example, some children were missed on
day 7, but were seen again on day 14. These children have
been included in the analysis and in the study profile.
Clinical treatment failure.One child in the CQ group (a
two-year-old boy) died of malaria before completing full
treatment and was treated in the analysis as an early treat-
TABLE 1
Characteristics of recruited patients at presentation*
Chloroquine
(n  136)
Chloroquine plus artesunate
(n  400)
Age, years, mean (SD) 4.9 (2.32) 4.9 (2.29)
PCV, mean packed cell, volume, % (SD) 31.4 (5.36) 31.4 (5.06)
Plasmodium falciparum density, mean log/L (95% CI) 10.1 (6.21–13.19) 10.3 (6.21–13.0)
Temperature (°C), mean (95% CI) 37.9 (37.67–38.12) 37.9 (37.75–38.02)
% monthly recruitment (Oct:Nov:Dec) (36.7:54.4:8.8) (44.0:49.0:7.0)
Presence of gametocytes (prevalence) 20.6% 20.0%
* PCV  packed cell volume; CI  confidence interval.
FIGURE 1. Study profile. CQ  chloroquine; AS  artesunate; clin. fail.  clinical failure.
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ment failure. This child satisfied all inclusion criteria and was
recruited on a Monday around noon. He received the second
dose at home on Tuesday morning, but his condition rapidly
deteriorated. He was taken by his family to the pediatric ward
of Farafenni Hospital where he died on Tuesday night. Of
those children not lost to follow-up, there were no other
deaths of recruited children.
Of the 536 children recruited into the study, treatment out-
come was known for 428 (80%). At any time over the four
weeks of follow-up, CQ-treated children were more likely to
experience treatment failure than children who received CQ
plus AS (Figure 2), but this difference was not significant at
the 5% level. Fifty-two children were found during the four-
week follow-up period to have a continuation or recurrence
of clinical malaria, 17 (12.5%) and 35 (8.8%) children en-
rolled in the CQ and CQ/AS groups, respectively. An addi-
tional five children (4 and 1 in the CQ and CQ/AS groups,
respectively) harbored parasites on day 3 at 25% of the
pre-treatment parasite density on day 0,12 but were not con-
sidered clinical treatment failures under our protocol. Ka-
plan-Meier estimates of the treatment failure rates were 15%
(95% confidence interval [CI]  9.2−22%) and 11%
(7.8−15%), respectively (2  3.03, P  0.08, by Wilcoxon
test for equality of survivor functions). Finger prick blood
samples taken at the first follow-up visit after rescue-
treatment with SP were available for 21 of these children.
Seventeen of these 21 children (81%) were successfully
cleared of asexual parasites, while the remaining four children
had persistent asexual parasitemia following administration
of SP, suggesting further (asymptomatic) treatment failure.
Although the combination provided a benefit in terms of
increased treatment success, this benefit was transient, and
was seriously eroded between day 14 and day 28 (Figure 2). In
fact, a highly significant difference in clinical failure rates
would have been observed if the study had been terminated at
14 days because prior to day 15 of follow-up there were 13
clinical failures among CQ-treated children (Kaplan-Meier
estimate 11%, 95% CI 6.5−18%) and only seven among
CQ/AS-treated children (2%, 95% CI  0.9−4.1%; 2 
17.4, P < 0.001) (Figure 2).
Age and clinical failure. In both treatment groups, treat-
ment failure was significantly higher among children less than
five years old (hazard ratio  1.8, 95% CI  1.04−3.2, P 
0.035) (Table 2). Treatment failure rates were also higher
among children treated in October, the first month of recruit-
ment, than in November/December (hazard ratio 1.8, 95%
CI  1.01−3.1, P  0.045).
Parasitologic treatment failure. Children with a thick film
positive for P. falciparum trophozoites in the absence of fever
or other clinical signs of malaria during follow-up were con-
sidered asymptomatic parasitologic treatment failures and
were not given SP as rescue treatment. Parasitologic analysis
was restricted to children known to have completed the treat-
ment course that had presented at enrollment with a con-
firmed P. falciparum infection of at least 500 parasites/L
(n 472, 120 and 352 in the CQ and CQ/AS groups, respec-
tively). We chose this “on-treatment” approach specifically
to evaluate the parasite-killing effect of the full three doses
of AS.
The prevalence of parasitemia during the follow-up period
is shown for both treatment groups in Figure 3. At each time
point, the prevalence of trophozoites was significantly higher
among children treated with CQ than among those treated
with CQ/AS (2 92.98, 40.09, 21.16, and 12.67, respectively,
P < 0.001 in each case). Among fully treated children, 49.1%
in the combination group and 73.3% in the monotherapy
group experienced at least one episode of parasitemia, with or
without symptoms of clinical malaria (relative risk  1.49,
95% CI  1.28−1.74, 2  21.18, P < 0.001). Thus, the com-
bination confers a significant benefit in reducing carriage of
FIGURE 2. Kaplan-Meier estimates of clinical failure rates after treatment with chloroquine (CQ) and CQ plus artesunate (AS). The plots
represent numbers of children at risk in each group at each time point.
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parasites after treatment compared with monotherapy, albeit
with a cumulative anti-parasite efficacy over 28 days of only
51%.
Trophozoite density among parasite-positive subjects in-
creased from day 3 during follow-up in both treatment groups
(Figure 4). The mean natural logarithm (ln) of the parasite
density was significantly lower in the combination group on
days 3, 7, and 14. The significant reduction in parasite density
seen in the first week post-treatment among children treated
with the combination was partially eroded by day 14, and by
day 28 there was no difference in mean ln parasite density
between the treatment groups (Figure 4). This is consistent
with the hypothesis that parasitemia occurring late in follow-
up is largely derived from the expansion of low or undetect-
able populations of parasites that survive treatment.4
Since parasite densities are affected by immune responses
of the host, age may be expected to have an effect on this
parameter. For example, presentation parasitemia was on av-
erage higher among children less than five years old, and this
difference was significant at the 10% level. Among children
harboring trophozoites during follow-up, there was a similar
small effect of age on parasite density at day 7. Children less
than five years old who were parasite positive had an average
density of 3,777 (95% CI  ± 2,340) parasites/L at day 7,
whereas for those more than five years old, the average den-
sity was 1,966 (95% CI  ± 1,544) parasites/L (P  0.101,
by one-sided t-test). There was no discernable effect of age on
parasite density at any other point in follow-up.
DISCUSSION
We have shown that Gambian children with uncomplicated
falciparum malaria who receive a three-day regimen of CQ
plus AS exhibit a clinical failure rate of 11% and a cumulative
parasitologic failure rate of 52.1% over a 28-day period. This
regimen is thus much less efficacious in the Farafenni area
than is a three-day regimen of AS combined with a single
dose of SP, which has a treatment success rate of more than
97% in The Gambia.8,13 Although CQ/AS does provide a
transient benefit in clinical efficacy over CQ monotherapy
(Figure 2), a transient benefit in reducing parasite density
(Figure 4), and a more robust benefit in reducing the preva-
lence of post-treatment asexual parasitemia (Figure 3), we
conclude that CQ/AS would not be a suitable choice to re-
place CQ as the first-line antimalarial regimen in the Gambia.
The poor efficacy of the combination is likely to be caused
by the moderately high prevalence of CQ-resistant parasites
in the study area.4 Studies carried out in 1998 found that the
parasitologic efficacy of CQ over a 28-day period was ap-
proximately 70%.13 The results presented herein clearly show
that two years later, only 25% of the CQ-treated children did
not have an episode of post-treatment parasitemia, which sug-
gests that the prevalence of resistant parasites has increased
markedly. Artesunate is extremely effective at rapidly reduc-
ing parasite biomass, but only for a matter of hours after
being administered and a seven-dose course of AS mono-
therapy has been considered necessary to effect radical
cure.14,15 Thus, a small number of parasites can escape the
three-dose regimen in some patients, as we have shown re-
cently using a reverse transcriptase−polymerase chain reac-
tion.16 It follows that in a patient population with a significant
prevalence of CQ-resistant parasites, a proportion of these
will be able to recrudesce because of their resistance to CQ,
which persists at effective levels in the blood for six weeks.17
It is therefore very unlikely that replacement of CQ mono-
therapy with the CQ/AS combination would significantly slow
the increasing prevalence and distribution of CQ-resistant
parasites in The Gambia.
A striking feature of our data is that, compared with CQ
monotherapy, CQ/AS reduces the proportion of early clinical
treatment failures, but that over a 28-day follow-up period
there is little overall reduction in failures (Figure 2). A similar
transient benefit of the combination compared with CQ alone
is seen in the first week as a significant reduction of mean
positive parasite density among those children treated with
CQ/AS. By day 14, this difference remains significant but has
decreased, and it has disappeared by day 28 (Figure 4). Thus,
if we had used a standard 14-day protocol to compare the
sensitivity of our parasite population to the two regimens
used,12 we would have concluded that CQ/AS confers a sig-
nificant reduction in the proportion of clinical treatment fail-
ures and in mean positive parasite density. Following patients
to day 28 demonstrates that these benefits are transient, and
that re-treatment is eventually needed for a substantial num-
ber of children with malaria who are treated with CQ/AS.
These findings are consistent with the results from two recent
FIGURE 3. Prevalence of Plasmodium falciparum trophozoites in
fully treated children at each of the four time points following treat-
ment with either chloroquine (CQ) or CQ/artesunate (AS). The de-
nominators are Day 3, 113 and 338 children, respectively, in the
monotherapy and combination groups; Day 7, 108 and 326 children;
Day 14, 102 and 307 children, and Day 28, 96 and 280 children.
TABLE 2
Kaplan-Meier estimates of clinical failure rates (95% CI) with
age stratification*
CQ CQ plus AS
Day 14 <5 years old 15% (8.0 ,2.7) 3.2% (1.3, 7.5)
5 years old 6.8% (2.6, 17) 1% (0.3, 4.0)
Day 28 <5 years old 19% (11, 31) 15% (10, 22)
5 years old 10% (5, 22) 7.8% (5, 13)
* CI  confidence interval; CQ  chloroquine; AS  artesunate.
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studies using other drug combinations. Adjuik and others18
used a 28-day design to evaluate the relative efficacy of amo-
diaquine versus amodiaquine/AS, and found lower cure rates
at day 28 than at day 14. Dorsey and others19 obtained a
similar result in Uganda when treatment with SP was com-
pared with SP plus AS. There, the best combination was SP
plus amodiaquine. We would argue that longer follow-up pro-
vides a much more accurate picture of how well drugs work in
the field, and that study protocols should always include fol-
low-up beyond the two-week mark especially when combina-
tions include drugs with long half-lives.
The transient nature of the benefit of the CQ/AS combi-
nation is consistent with the hypothesis that among CQ-
treated children in the Farafenni area, most or all post-
treatment parasitemia is caused by recrudescent parasites
rather than reinfection. We have argued that the crucial dif-
ference between RI, RII, and RIII patterns of recrudescence
in CQ-treated children is the proportion of the original infec-
tion made up of CQ-resistant parasites.4 If this proportion is
very low, and thus below the level of detection by microscopy,
the patient will appear to clear the infection immediately fol-
lowing treatment, and any subsequent parasitemia arising
from the expansion of this small remnant will appear as an RI
type, or perhaps be considered a new infection, even with
molecular strain typing.
Among parasites exposed to the combination, we envisage
that the vast majority of both CQ-resistant and CQ-sensitive
genotypes will be killed in the hours that follow administra-
tion of each dose of AS. The chance of a recrudescence oc-
curring will then depend on the proportion of CQ-resistant
parasites among the remnant that escape these three doses of
AS. Therefore, we would predict that recrudesence of resis-
tant parasites among combination-treated patients will take
longer to reach patency and occur less frequently than among
patients treated with CQ monotherapy. This is what we have
observed. We are currently undertaking a comprehensive ge-
notype analysis of parasite DNA collected from this study to
test this hypothesis. Preliminary genotyping experiments with
20 parasite isolates from children in the CQ/AS group that
were thick-film-positive on day 14 found that 19 of the chil-
dren harbored parasites with CQ resistance−associated alleles
at the pfcrt locus (Ord R and Sutherland CJ, unpublished
data).4 This suggests that gametocytes emerging after treat-
ment with the combination may also be selected for CQ re-
sistance, as we have previously shown among gametocytes
emerging after CQ monotherapy.4
Our results show that one highly effective antimalarial
(AS) plus one relatively ineffective antimalarial (CQ) equals
a poor combination. However, in contrast, the addition of AS
to vulnerable and failing mefloquine in northern Thailand
proved highly efficacious, and contributed to a significant re-
duction in gametocyte carriage rates.20 The Thai study popu-
lation may not be comparable to African settings such as The
Gambia because few exposed people have acquired immunity
against malaria and asymptomatic infections are very rare.
Nevertheless, it is simplistic to regard drug combinations as
simply additive; important interactions between two drugs
may occur on a number of levels including cross-resistance,
inverse selection where one drug selects for a genotype con-
ferring sensitivity to the other drug, and antagonism.21,22
Thus, empirical testing of apparently rational combinations in
different endemic settings is essential to determine which are
appropriate in each of those settings.
In conclusion, we have shown that the combination CQ/AS
FIGURE 4. Mean natural logarithm (ln) trophozoite density in children who were fully treated with either chloroquine (CQ) or CQ/artesunate
(AS). The mean of the natural logarithm of parasite density among slide-positive children is shown for each time point. Bars show the 95%
confidence intervals of the mean. Differences between means were tested by the Student’s t-test. *significance at the 5% level; **significance at
the 1% level.
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is not sufficiently efficacious to justify its introduction as a
first-line treatment regimen for malaria in The Gambia, de-
spite it having some measurable benefits over CQ mono-
therapy. Our evidence also suggests that use of the combina-
tion would do little to reduce the transmission of CQ-resistant
parasites in our study area. The major reason for the poor
efficacy of this combination in the Farafenni area appears to
be the already moderate-to-high prevalence of CQ-resistant
P. falciparum infections. Therefore, this combination may yet
prove to be useful against P. falciparum in settings where CQ
resistance is rare, or in settings where P. vivax is the major
malaria pathogen and sensitivity to CQ remains high. This
precautionary measure may prevent the emergence or further
selection of CQ-resistant vivax malaria.
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